Pharmaceutical Commerce August 2026

Ed Schoonveld examines how AI is reshaping drug pricing and access, from payer decisions to prescribing, and what it means for new drug treatments.

Across pricing, supply chain, and patient support, the playbooks of pharma commercialization are being rewritten at once for a new era.

The models pharma inherited were built for conditions that have changed. A look across the August issue at an industry redesigning itself.

Specialty drugs, cell and gene therapies, and GLP-1s are reshaping pharma distribution, forcing 3PLs to build for both precision and scale.

Manufacturers must forecast and commercialize products across commercial, government and cash economies to maximize lifetime enterprise value.

Generating real-world evidence isn't enough. What drives market access is whether payers can actually evaluate and act on it.

Four patient services veterans on what's driving hub transitions in 2026, the digital tools reshaping how support is delivered, and what manufacturers need to get right to keep patients on therapy.

Cold chain packaging was built for a stable world. As disruption becomes the norm, pharma logistics teams are rethinking what control actually means and when it has to happen.

AI-powered automation is transforming pharmacovigilance, cutting AE case intake time amid record FAERS volumes and new FDA/EMA regulatory guidance.

Early launch planning, streamlined patient access, and measured AI adoption help specialty therapy programs accelerate treatment and sustain success.

Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.

Post-approval changes are overwhelming pharma ops teams. Here's why lifecycle change management has become one of the industry's most consequential and overlooked operational risks.